TrueMark Investments LLC Has $713,000 Position in Schrödinger, Inc. (NASDAQ:SDGR)

TrueMark Investments LLC trimmed its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 7.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,946 shares of the company’s stock after selling 3,054 shares during the period. TrueMark Investments LLC owned about 0.05% of Schrödinger worth $713,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Paradigm Asset Management Co. LLC acquired a new position in Schrödinger during the fourth quarter valued at approximately $50,000. Quarry LP raised its stake in shares of Schrödinger by 1,150.0% during the 3rd quarter. Quarry LP now owns 2,825 shares of the company’s stock worth $52,000 after purchasing an additional 2,599 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Schrödinger by 87.5% in the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock valued at $54,000 after buying an additional 1,305 shares during the last quarter. KBC Group NV grew its stake in shares of Schrödinger by 73.9% in the fourth quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after buying an additional 1,853 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Schrödinger during the third quarter worth $102,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SDGR shares. KeyCorp lifted their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Piper Sandler reduced their price target on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Schrödinger has a consensus rating of “Buy” and an average price target of $32.29.

Insider Transactions at Schrödinger

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at approximately $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

Schrödinger Stock Down 5.7 %

Schrödinger stock opened at $21.45 on Wednesday. The company’s 50-day moving average price is $23.03 and its two-hundred day moving average price is $20.79. The stock has a market cap of $1.57 billion, a P/E ratio of -9.17 and a beta of 1.62. Schrödinger, Inc. has a twelve month low of $16.67 and a twelve month high of $29.15.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Equities analysts anticipate that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.